Cord Blood Registry

About:

Cord Blood Registry is the world’s largest newborn stem cell company.

Website: https://www.cordblood.com

Twitter/X: CordBlood

Top Investors: HLM Venture Partners, ABS Capital Partners, Essex Woodlands Healthcare Partners

Description:

Since the company’s founding, Cord Blood Registry® (CBR®) has led the industry in technical innovations and provided families with access to current treatments and experimental stem cell therapies for conditions that have no cure. Cord Blood Registry (CBR) is the world’s largest newborn stem cell company. Founded in 1992, CBR is entrusted by parents with storing samples from more than 500,000 children. CBR is dedicated to advancing the clinical application of cord blood and cord tissue stem cells by partnering with institutions to establish FDA-regulated clinical trials for conditions that have no cure today. CBR has helped more than 300 families use their cord blood stem cells for established and experimental medical treatments, more than any other family cord blood bank. CBR’s goal is to expand the potential scope of newborn stem cell therapies that may be available to patients and their families. Cord Blood Registry is headquartered in San Bruno, California. CBR’s owned 80,000 square foot laboratory is located in Tucson, Arizona. Cord Blood Registry is a registered trademark of CBR Systems, Inc. CBR maintains standards for cellular therapy services through AABB accreditation, FDA-registration, and CLIA certification. CBR has the longest history of accreditation with the AABB (formerly known as the American Association of Blood Banks) and the company’s quality standards have been recognized through ISO 9001:2008 certification — the global business standard for quality. A pioneer in newborn stem cell collection and cryopreservation, CBR believes in the power of newborn stem cells to improve lives today and their potential to revolutionize treatment for many conditions in the future. CBR is the first family newborn stem cell bank to partner with leading research institutions to establish FDA-regulated clinical trials exploring the potential regenerative ability of stem cells to help treat conditions that have no cure today, including: acquired hearing loss, autism, cerebral palsy, and pediatric stroke. In fact, 73% of the stem cell units released by CBR have been used for experimental regenerative therapies – more than any other family cord blood bank in the world.